GLP-1 medications like Ozempic cause slowed gastric emptying, which often leads to delayed or blunted effects when taking oral psychedelics like psilocybin or MDMA. To ensure a consistent therapeutic experience, many users are exploring alternative routes of administration and investigating the benefits of combining them in one’s healing journey.
Key Takeaways
- Impact on Psychedelics: Because GLP-1s cause slowed gastric emptying, they can lead to delayed or blunted effects, with some (but not all) users reporting onset times of 2–6 hours or significantly weakened experiences.
- Alternative Methods: To bypass digestive delays, users can consider alternate routes of administration such as sublingual lozenges, nasal sprays, or inhalation, which allow the compounds to enter the bloodstream directly.
- Therapeutic Synergy: Emerging research suggests a powerful combination potential for treating addiction and obesity from using both GLP-1s and psychedelics.
- Psychedelic Passage: Your Psychedelic Concierge — The easy, legal way to find trustworthy psilocybin guides, facilitators, and psychedelic-assisted therapy near you in the United States.
Did you know that Ozempic’s story began with a Gila monster? The active ingredient, semaglutide, was actually derived from exendin-4, a peptide found in the venom of the Gila monster.
GLP-1s (also called GLP-1 RASs), like Ozempic, have recently been shown to have potential mental health benefits, as well as physical benefits, and, whether we want to admit it or not, weight loss has a mental component.
So many of us have tried diets and exercise regimens without seeing much of a difference on the scale, and working toward a goal without seeing progress can seem futile. It’s easy to lose motivation toward something that isn’t showing results. That’s just human nature.
Clinical psychologist Rachel Goldman says, “For individuals struggling with obesity—and for anybody who tries to make a behavior change over and over again without success—they think something’s wrong with them. They internalize that bias. There’s shame; there’s guilt. And that really gets in the way of them continuing to try. But the GLP-1s put them on an even playing field” (Medaris, 2025).
About 1 in 8 Americans report trying a GLP-1, while more and more Americans are investigating psychedelics for mental health treatment.
For a medication that’s knocked psychedelics out of the limelight (for now), it’s something worth investigating for us at Psychedelic Passage.
We’ll look at what exactly this popular class of drugs is, why the interaction between psychedelics and GLP-1s matters, and what current research and anecdotal evidence is saying, while giving some practical tips on how to mitigate possible negative side effects.
Download Our Free Psilocybin Sourcing Guide
For harm-reduction purposes, we provide links to online psilocybin vendors, local stores, delivery services, and spore vendors for growing your own medicine at home.
What Are GLP-1s?
You may have heard the terms “GLP-1,” “semaglutide,” or “tirzepatide” recently, or at least one of the many brand names flooding the market like Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Victoza, or Byetta, but what exactly is this type of medication, and how does it interact with psychedelics?
Here are some basic facts about GLP-1 medications like Ozempic:
- They target weight loss and glucose control for type 2 diabetes.
- They do this by binding to receptors in the pancreas, brain, and gastrointestinal tract, disrupting natural hunger signaling by increasing insulin release, inhibiting glucagon, and delaying stomach emptying.
- Also called “incretin mimetics,” they mimic the effects of incretin hormones, which are produced in the gut and stimulate insulin and glucagon release.
- GLP-1s are being researched for numerous applications, like lowering cardiovascular risk factors, while also being prescribed off-label for addiction, gaining popularity fairly quickly.
- Given their long half-life, most are given by weekly injection; Rybelsus is in pill form.
- They also curb appetite and addictive behavior by releasing dopamine, the neurotransmitter linked to motivation, pleasure, and reward.
- Their mechanism of action determines the scientific term for them: glucagon-like peptide-1 receptor agonists or GLP-1 receptor agonists, and there are also popular analogues that are glucose-dependent insulinotropic polypeptide agonists, or GIP agonists.
- Research shows that it can take up to 5 months for tirzepatide (Zepbound/Monjaro) to reach an effective dose. It may take up to a year before you know if you’re a slow or non-responder.
GLP-1 side effects include:
- Most common: nausea, vomiting, diarrhea, and constipation.
- Dehydration can be caused by the above symptoms, so those taking GLP-1s need to drink more water than the average person to stay hydrated. This is important for those who are thinking about MDMA or other substances that can also cause dehydration.
- “Ozempic face,” which happens when there’s rapid loss of fat in the face, and might cause sunken eyes, hollow appearance, wrinkles, or sagging.
- Less common but more serious: pancreatitis, gastroparesis, bowel obstruction, blockages, or gallstones.
- When to seek medical attention: Severe vomiting, diarrhea, constipation or abdominal pain, especially accompanied by a fever, as well as jaundice (yellowing of the skin).
This New York Post article provides some valuable insights on the top reasons GLP-1 users end up in the hospital.
Information sourced from: GLP-1 diabetes and weight-loss drug side effects: Harvard Health.
Why GLP-1s Might Complicate Things
Delayed or Blunted Psychedelic Effects
As Ozempic spread like wildfire, anecdotal reports began stacking up, and a pattern emerged, but there’s one effect of GLP-1s that stood out the most when thinking about their effect on psychedelic use, and that’s the slowing down of gastric emptying. This effect can affect the absorption of other orally administered medications.
Our psychopharmacology consultant, Dr. Ben Malcolm, recently did a deep dive of his own, and he’s collected many reports that show a trend: the expected effects of oral psychedelics like psilocybin, MDMA, and ayahuasca don’t start in the expected timeframe when accompanied by a GLP-1.
Because GLP-1 agonists slow down gastric emptying significantly, those ingesting psilocybin mushrooms began reporting delayed onset of psychedelic effects, blunting effects, or no psychedelic effects felt at all from the mushrooms.
If it were only one or two instances, you might think they just got an old or weak batch of mushrooms, but even when the mushrooms tested extra potent, users reported unpredictable results when taken with a GLP-1.
We don’t have any studies on this particular drug interaction, but we do have evidence from pharmacokinetic probe experiments that the absorption of Tylenol (acetaminophen or paracetamol), for example, is delayed for up to an hour, specifically when people have just started a weight loss medication or are in a titration phase.
Dr. Malcolm’s anecdotal reports show that those on GLP-1s have an onset of effects 2–6 hours after administration of a psychedelic, which is way more varied than the usual 30–45 minute onset.
These reports have also shown the psychedelic effects to be weaker, but to last longer than a typical experience, often dropping off unexpectedly. Sometimes, “non-event” experiences were reported with no noticeable effects.
Because of the preliminary experiments with Tylenol, Dr. Malcolm says the delayed onset of psychedelic effects that are being reported is to be expected.
How to Mitigate The Delayed or Blunting Effects of GLP-1s
The idea of tapering off certain medications prior to a psychedelic experience is nothing new. It’s a deeply personal decision that only you can know is right for you, but it helps to have a professional opinion to consider.
GLP-1s have a long half-life, meaning that the drug stays in your system for a longer amount of time than something like aspirin. We’ve had clients decide to taper off their low-dose GLP-1 for a month before their ceremony, which seemed like an appropriate amount of time needed to mitigate the delayed and blunting effects.
We’ve also had clients skip one dose (assuming they take weekly injections), while scheduling the doses before and after to achieve the longest possible cessation period, rounding out to about 2 weeks.
Interestingly, we’ve had clients forget to skip their dose, and have no noticeable blunting or delayed psychedelic effect, and clients who saw a delay but no blunting of the experience.
Unfortunately, with individual differences and a lack of research, it’s difficult to say what determines the interaction between GLP-1s and psychedelics.
However, not everyone wants to or can taper off their medications, and we think that’s fine! We believe in radical sovereignty when it comes to putting anything into your body. We also believe in arming you with all the information you need to make an informed decision.
So, what options are there for folks who don’t necessarily want to taper off of their GLP-1?
Intranasal, intravenous, and intramuscular, even sublingual administration of psychedelics can curb the undesirable and unpredictable effects of delayed onset or weakened effect. Psychedelics that utilize inhalation of smoke, like DMT, can also curb these effects.
The Case for Sublingual Psilocin
The first inkling of this idea came from a private Signal group, but it quickly began to spread and be theorized about: psilocin lozenges can bypass the digestive system by being absorbed through sublingual (under the tongue) or buccal (cheek pouch) administration.
See, psilocybin is a prodrug, meaning in order for it to have an effect, it must get absorbed and converted in our body into psilocin—the compound that interacts with our serotonin receptors.
The good thing is psilocin is available in lozenges, as are substances like LSD and ketamine, so this theory can be put to the test in the future to bypass the issue of digestion for those who take GLP-1s or similar medication and would prefer not to taper off of them.
Joshua Woolley’s study, Comparing the Effects of Psilocin and Psilocybin in Healthy Adults, at the University of San Francisco, may illuminate some key differences that add to the story of GLP-1s and psilocybin, but as of February 2026, we’ll have to wait for the data.
Did you know? Ozempic’s active ingredient, semaglutide, was derived from exendin-4, a peptide found in the venom of the Gila monster.
Current Research on Psychedelics & GLP-1s
When mixing any substance or medication, it’s extremely important to know any possible interactions.
We’ve explored SSRIs in depth, and now that GLP-1s are gaining popularity, it’s time to take a look at what the research is beginning to show when they’re combined, including potential benefits and side effects.
Ketamine
Ketamine is one substance with little interaction with GLP-1s because all methods of administration bypass the digestive tract, but there’s one symptom that can be exacerbated when taken together: Nausea.
Nausea is a common symptom of both ketamine and GLP-1s, so it might be helpful to monitor your nausea level, stick to a light, healthy meal before ketamine sessions, and think about keeping antinausea medication like Zofran on hand.
Addiction, the Reward Center, & Neuroplasticity
Researchers at Stanford & NYU investigated the therapeutic potential of GLP-1s in treating Alcohol Use Disorder (AUD) by collecting past research on the neuromechanisms of addiction and GLP-1s. In doing so, they’re able to direct future research and highlight gaps in the current research.
They found that GLP-1s do show encouraging results in treating AUDs, but actual research into their potential role in addiction medicine needs to be further explored.
Here’s where it gets interesting: both GLP-1s and psychedelics act on the brain’s reward centers (ventral tegmental area and nucleus accumbens). Lodetti et al. 2024 found that “psychedelic substances have demonstrated potential for treating drug addiction, especially AUD, mostly by modulating neuroplasticity in the brain.”
Both of these studies are speculative, although the evidence that they collected was promising. Much more research needs to be done in order to determine the full extent of the relationship between GLP-1s, psilocybin, and addiction.
Depression & Quieting “Food Noise”
We’re beginning to see that sometimes, two (or three, or four) is better than one. Whether it’s a medicinal mushroom, a meditation practice, or a therapist, we’re all for adding more layers to your healing journey.
The relationship between GLP-1s and mental health is largely unknown, and what we do know is from anecdotal reports. Until 2026, all research used populations that excluded most mental health diagnoses, which is standard practice to collect clear data.
The first trial that tested a GLP-1 in a population with a mood disorder was published in January 2026 by Badulescu et al in Canada, to see if semaglutide (Ozempic) was a viable treatment of cognitive dysfunction in major depressive disorder (MDD), using 72 participants over the course of 16 weeks.
They found that the GLP-1 semaglutide did not improve executive function in MDD; there were no effects on depressive symptoms or suicidal ideation, which is a major finding.
Back in 2023, research actually showed that GLP-1s could help curb obsessive thought and rumination, at least in relation to food.
Research done by Hayashi et al., 2023 showed that GLP-1s can affect thoughts as well as cravings and metabolism, and have been reported to “quiet food noise,” meaning that “anecdotal reports from patients and clinicians alike point to a reduction in what has been colloquially termed ‘food noise’, as patients report experiencing less rumination and obsessive preoccupation about food.”
The same neuroplasticity benefits that psilocybin could offer for those recovering from addiction could also be applied to those looking to rewrite their brain patterns in relation to food.
When a medication like Ozempic lowers the risk for obsessive thoughts and rumination, new thought patterns can be formed, meaning that GLP-1s may not have to be “forever medications” when used in tandem with psilocybin to form and solidify new thought patterns.
Improved Liver Function
In February 2025, Colognesi et al. (2025) examined the effects of administering semaglutide (Ozempic) and psilocybin in mice with fatty liver disease, now referred to as steatotic liver disease.
Researchers fed mice a high-fat, high-fructose diet. They then administered 40 mcg of semaglutide twice weekly and 0.05 mg/Kg of psilocybin daily, either alone or in combination, and included a control group on a standard diet.
They found that weight gain was significantly reduced by all treatments, but particularly with the semaglutide-psilocybin combination. The combination also preserved muscle function and improved insulin sensitivity, which indicates potential benefits of combination therapy.
Get Your Free Medication Interaction Resource
Understand potential medication & psychedelic interactions in this free 59-page PDF.
Emerging Concerns on Physical Side Effects
The promises that GLP-1s, like Ozempic, bring to the table are obviously garnishing a lot of attention, and even though they show fast results, some of us might fall into the trap of “more is better.” This might cause some to redose too quickly or take a higher dose than they should, in an effort to achieve faster results.
While two decades of research show that GLP-1s are generally safe, with benefits outweighing risk, in fact, many “safe” things become dangerous in large quantities – even something like water.
This is all to say that taking shortcuts doesn’t always yield better results, we care about you, and your body is a temple!
Rapid Muscle Loss
A few studies have found rapid loss of lean body mass, including skeletal muscle mass, that’s associated with GLP-1 use (Ceasovschih et al., 2025). This concern can be mitigated by paying close attention to dosage, exercise, diet, and symptom tracking.
It’s important to note that some things mask problems, while others fix problems at the root. While SSRIs might mask or dampen negative emotions, the same could be true for GLP-1s used for weight loss.
For a medication that can make you not eat, vomit, or have diarrhea, it’s important to be aware of the nutrient deficiencies that can be caused by prolonged symptoms such as these. For example, restrictive eating disorders have detrimental effects on bone and muscle mass, overall nutritional health, and dental health.
We know that a significant percentage of patients using GLP-1s not only can suffer from rapid muscle loss, but can also develop essential vitamin and mineral deficiencies within a year (The Hidden Danger of Using Weight-Loss Medications).
This can be problematic for those of us who already suffer from deficiencies due to something like a poor diet, but also for those of us looking to take a psychedelic with more of a “bioload” like MDMA. Arming your body with all the nutrients it needs can ensure the most beneficial experience, both mentally and physically.
Our bodies don’t just run on thin air or potato chips, although it’d be nice if they did. We need whole foods and a balanced diet to get all the happy chemicals we can muster, and if you care enough to try GLP-1s or psychedelics, then a conversation about diet fits nicely into the conversation.
Recommended Reading: Psilocybin and Psychedelic Therapy for Weight Loss
In Conclusion
While GLP-1s can help kickstart a physical component to your overall healing journey, they introduce unique challenges for those exploring psychedelic therapy.
Luckily, fellow humans have already been conducting research and investigating ways to circumvent the physical barriers posed by slowed gastric emptying via alternate routes of administration, such as sublingual psilocin melts.
Modern medicine is a blessing, but it’s not a catch-all or an easy fix, and it still carries risks. It’s easy to pass the responsibility off to our doctor, but we have a responsibility to ourselves to do our own due diligence, too.
Ultimately, the synergy between these two classes of drugs suggests a future where weight loss and mental rewiring work in tandem, provided we treat the body with the informed care and respect it deserves.
Get Matched with a Trusted Psychedelic Coach Near You
Hi there! We sincerely hope that you’ve found valuable takeaways that resonate with your current intentions. To explore research-based education, stay updated with psychedelic news, and benefit from practical how-to articles, we encourage you to head over to our resources page.
If you’re seeking personalized advice and are prepared to take the first step toward a therapeutic psychedelic experience, we invite you to book a consultation with our team of experienced psychedelic concierges.
This consultation is more than just a conversation; it’s an opportunity to be matched with a trustworthy local facilitator. You’ll be seamlessly connected to our rigorously vetted network of psychedelic guides, ensuring potential matches align with your needs.
Psychedelic Passage offers confidence and peace of mind by alleviating the burden of having to guess who’s right for you. If you want to discover how Psychedelic Passage can help you, we empower you to learn more about our services and check out client testimonials from those who’ve gone before you.
Your healing path is uniquely yours, and our commitment is to serve you at every juncture. Psychedelic Passage: Your Psychedelic Concierge — The easy, legal way to find trustworthy psilocybin guides, facilitators, and psychedelic-assisted therapy near you in the United States.
Further Insights into Intentionality and Healing
Enjoy a compilation of some of our best resources on everything psychedelic, from pets to parenting.
- Understanding the Psychedelic Transformation: From recreational exploration to therapeutic healing, examine the evolving nature of psychedelic experiences and their impact on internal narratives about personal growth.
- Are Fur Babies Welcome? Our pets are there through it all, so it only makes sense to wonder if they should attend your psychedelic ceremony too.
- Nowadays, Everything’s on Film: Recording your psychedelic experience comes with considerations, but it can be beneficial for documentation or artistic purposes as well.
- A Beginner’s Psychedelic Dictionary: Learn what “psychedelic therapy” really means in America, when most of the substances aren’t federally legal.
- Psychedelics & Parenting: Being mindful of yourself isn’t the only thing that comes with expanded awareness; learn how it can affect your family dynamics and motherhood as well.
- Post-Trip Emotional Processing: Explore the many different types of psychedelic integration and how they affect you after a psychedelic experience.
Learn More About Our Network
- Book a Consultation Call
- Meet Our Referral Network
- Explore Frequently Asked Questions
- Watch Client Testimonials
- Is Psychedelic Passage Safe & Legit?
More Psychedelic Passage
- Listen to our podcast on Spotify or Apple Podcasts
- Subscribe to our YouTube Channel
- Follow us on Reddit
Frequently Asked Questions
1. Why does a weight-loss drug affect how long it takes for a psychedelic to kick in?
The primary culprit is slowed gastric emptying. GLP-1 medications tell your stomach to hold onto food (and pills) longer to make you feel full.
Because oral psychedelics like mushrooms or MDMA need to pass through the stomach to be absorbed in the small intestine, they get stuck in a “digestive logjam,” pushing the onset from the usual 45 minutes to as long as 6 hours.
2. If the effects are “blunted,” can I just take a higher dose of psychedelics?
This is generally discouraged because the interaction is highly unpredictable. While some report weaker effects, others experience drops off and restarts unexpectedly. Taking a higher dose could lead to an overwhelming “delayed hit,” potentially causing an intense experience at an unexpected time.
3. Can I bypass the digestive issues without stopping my GLP-1 medication like Ozempic or Mounjaro?
Yes. Users have found that alternate routes of administration that skip the stomach entirely are effective at mitigating digestive issues.
Using sublingual (under-the-tongue) lozenges, nasal sprays, or inhalation (such as DMT) allows the medicine to enter the bloodstream directly. This allows you to maintain your GLP-1 regimen while ensuring the psychedelic effects remain predictable and potent.
4. Could psychedelics actually help me stop taking GLP-1s eventually?
Potentially. While GLP-1s chemically quiet “food noise” or obsessive thoughts associated with eating, psychedelics promote neuroplasticity, which can help “rewire” the underlying behavioral patterns.
Using them in tandem might allow a person to solidify new thought patterns, potentially making the GLP-1 a temporary tool rather than a lifelong requirement.
It’s important to note that eventual cessation of a GLP-1 doesn’t necessarily need to be the end goal, and everyone should choose whatever path they find most conducive to their healing goals.
5. Why is hydration more critical for GLP-1 users during a psychedelic ceremony?
Both GLP-1s and certain psychedelics (like MDMA) can stress the body’s fluid balance. GLP-1s often cause nausea or diarrhea, leading to baseline dehydration.
When you add a substance that increases body temperature or physical exertion, the risk of severe dehydration or electrolyte imbalance spikes, making diligent water intake a safety priority.
6. Is there a biological benefit to combining these two types of drugs?
Early research suggests there is. Beyond mental health, a 2025 study in mice found that a combination of semaglutide and psilocybin was more effective than either treatment alone at reducing weight gain and improving insulin sensitivity.
They seem to work together to preserve muscle function and fix metabolic issues at the root, which is exciting for the future of this research. With both GLP-1s and psychedelics becoming increasingly popular, it will be interesting to see what else is uncovered.
References
Badulescu, S., Gill, H., Shah, H., Brudner, R., Phan, L., Di Vincenzo, J. D., Tabassum, A., Armanyous, M., Llach, C.D., Rosenblat, J. D., McIntyre, R. S., & Mansur, R. B. (2025). Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial. Med, 100916. https://doi.org/10.1016/j.medj.2025.100916
Catanese, L. (2024, February 5). GLP-1 diabetes and weight-loss drug side effects: Harvard Health. https://www.health.harvard.edu/staying-healthy/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025). Glucagon-like peptide-1 receptor agonists and muscle mass effects. Pharmacological Research, 220, 107927. https://doi.org/10.1016/j.phrs.2025.107927
Colognesi, M., Gabbia, D., Signor, A., Comai, S., Mattarei, A., Pasut, G., Folli, F., Centofanti, L., La Rosa, S., Finzi, G., Pappagallo, M., Manfredi, P., & De Martin, S. (2025). Beneficial effect of the combination psilocybin-semaglutide in a murine model of Steatotic Liver Disease. Digestive and Liver Disease, 57, S71. https://doi.org/10.1016/j.dld.2025.01.135
Hayashi, D., Edwards, C., Emond, J. A., Gilbert-Diamond, D., Butt, M., Rigby, A., & Masterson, T. D. (2023). What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients, 15(22), 4809–4809. https://doi.org/10.3390/nu15224809
Lodetti, G., de Bitencourt, R. M., & Rico, E. P. (2024). Classic psychedelics and the treatment for alcoholism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 135, 111129. https://doi.org/10.1016/j.pnpbp.2024.111129
Maideen, N. M. P. (2019). Pharmacologically relevant drug interactions of glucagon-like peptide-1 receptor agonists. J Anal Pharm Res, 8(2), 51-53. https://www.researchgate.net/profile/Naina-Mohamed-Pakkir-Maideen/publication/333746529_Pharmacologically_relevant_drug_interactions_of_Glucagon-like_peptide-1_receptor_agonists/links/5d01ce7d92851c874c6248d3/Pharmacologically-relevant-drug-interactions-of-Glucagon-like-peptide-1-receptor-agonists.pdf
Malcolm, B. (2025, December 17). Are GLP-1 Medications Like Ozempic Tripkillers? (2025). Spiritpharmacist.com. https://www.spiritpharmacist.com/blog/GLP1andPsychedelics_Tripkillers
Medaris, A. (2025). A new era of weight loss: Mental health effects of GLP-1 drugs. apa.org. https://www.apa.org/monitor/2025/07-08/weight-loss-drugs-mental-health
Semaglutide (Ozempic): From Lizard Spit to a Once-Weekly Wonder | OpenOChem Learn. (2026). Openochem.org. https://learn.openochem.org/learn/the-alchemy-of-drug-development/semaglutide-ozempic-from-lizard-spit-to-a-once-weekly-wonder
Srinivasan, N. M., Farokhnia, M., Farinelli, L. A., Ferrulli, A., & Leggio, L. (2025). GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer. Journal of the Endocrine Society, 9(11). https://doi.org/10.1210/jendso/bvaf141
The Hidden Dangers of GLP-1 Weight Loss Medications. (2025). Psychology Today. https://www.psychologytoday.com/us/blog/the-leading-edge/202512/the-hidden-dangers-of-glp-1-weight-loss-medications
